NCT05799651View on ClinicalTrials.gov

Safety and Immunogenicity of Glycovax-002 Vaccine in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

December 31, 2024

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

Glycovax-002

Intramuscular injection of vaccine against SARS-CoV-2

Trial Locations (1)

4006

Q-Pharm Pty Ltd, Herston

Sponsors
All Listed Sponsors
collaborator

Government of Canada

OTHER_GOV

collaborator

JSS Medical Research Inc.

INDUSTRY

collaborator

Avance Clinical Pty Ltd.

INDUSTRY

collaborator

Seppic

INDUSTRY

lead

Glycovax Pharma Inc.

INDUSTRY